-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Cidofovir dihydrate
![{PARAM:[Name]}({[CAS]})](https://resource.bocsci.com/structure/149394-66-1.gif)
| Category | Cytomegalovirus (CMV) |
| CAS | 149394-66-1 |
| Description | Cidofovir is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. It suppresses CMV replication by selective inhibition of viral DNA polymerase and therefore prevention of viral replication and transcription. It is an acyclic nucleoside phosphonate, and is therefore independent of phosphorylation by viral enzymes, unlike acyclovir. Cidofovir was discovered at the Institute of Organic Chemistry and Biochemistry, Prague, and developed by Gilead Sciences and is marketed with the brand name Vistide by Gilead in the USA, and by Pfizer elsewhere. Maintenance therapy with cidofovir involves an infusion only once every two weeks, making it a convenient treatment option. Because dosing is relatively infrequent, a permanent catheter is not necessary for infusions. |
Product Information
| Synonyms | HPMPC dihydrate; Vistide dihydrate; (S)-HPMPC dihydrate |
| IUPAC Name | [(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid;dihydrate |
| Molecular Weight | 315.22 |
| Molecular Formula | C8H18N3O8P |
| Canonical SMILES | C1=CN(C(=O)N=C1N)CC(CO)OCP(=O)(O)O.O.O |
| InChI | InChI=1S/C8H14N3O6P.2H2O/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16;;/h1-2,6,12H,3-5H2,(H2,9,10,13)(H2,14,15,16);2*1H2/t6-;;/m0./s1 |
| InChIKey | FPKARFMSZDBYQF-ILKKLZGPSA-N |
| Boiling Point | 609.5°C at 760 mmHg |
| Melting Point | 260°C (dec) |
| Flash Point | 322.4±34.3 °C |
| Purity | >98% |
| Density | 1.76 g/cm3 |
| Solubility | Soluble in DMSO |
| Appearance | White Powder |
| Application | Antiviral Agents |
| Storage | Store at RT |
| Complexity | 417 |
| Exact Mass | 315.08315154 |
| Index Of Refraction | 1.656 |
| PSA | 157.71000 |
| Target | CMV; DNA/RNA Synthesis; Orthopoxvirus; Apoptosis; Endogenous Metabolite |
| Vapor Pressure | 0.0±4.0 mmHg at 25°C |
Description of First Aid Measures
Eye contact
Remove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.
Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.
InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.
IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.